Revvity has announced a collaboration with biotechnology company Profluent to accelerate the development of novel gene-editing therapies.  The collaboration will bring together a range of Profluent’s novel AI-engineered enzymes with Revvity’s established Pin-point base editing platform, creating a therapeutically relevant base editing toolkit.  The new Pin-point configuration will allow for increased precision and efficiency in gene-editing, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!